Bigger Early Kidney Function Drops Signaled Higher Predicted Risk on Semaglutide and Placebo in New FLOW Analysis

A FLOW trial analysis found that larger early eGFR declines were linked to higher predicted kidney-event rates, but the association appeared with placebo too and did not prove semaglutide caused injury.